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Erdheim-Chester disease (ECD) represents a clonal non-Langerhans histiocytosis, which manifests under an extensive variety of
clinical symptoms. This creates a challenge for the physician, who is required to recognize and diagnose the disease in the early
stages. Despite this considerable challenge, in the last decade there has been a dramatic increase in ECD diagnoses, in most part
due to an increasing awareness of this rare disorder. Involvement of the axial skeleton is exclusively uncommon with no official
recommendations for the treatment of the bone lesions. Here, we present a case report of a young male patient with isolated lesions
of the spine, ribs, and pelvis, who was successfully treated with a combination therapy of alfa-interferon and zoledronic acid.
1. Introduction
Erdheim-Chester disease (ECD) is a rare non-Langerhans
histiocytosis of unknown etiology, characterized by focal or
systemic tissue infiltration of foamy histiocytes, which have a
particular tropism towards connective tissue.These cells typi-
cally share the immunophenotype FXIIIa+, CD68+, CD163+,
CD1a−, and S100−. The clinical picture ranges from mild
asymptomatic infiltration to severe cases, which are some-
times life-threatening. The disease is typically entrenched in
the long bones, but it may also affect the central nervous
system, retroperitoneal organs, the orbit, lungs, and other
organs. The spinal vertebrae are usually spared in ECD with
only two cases reported [1]. To date, the consensus guide-
lines for the diagnostics and treatment of ECD have been
collected and established [2], although the recommendations
regarding the therapeutic approach to bone lesions have not
been thoroughly discussed. It has been postulated that the
prognosis of the patient is determined by the extent and the
distribution of the extraskeletal manifestations of the disease;
simultaneously, data recording the clinical progression of the
patients with isolated bone lesions are lacking.
2. Case Presentation
A 28-year-old man presented in the clinic with pain in his
lower back and ribs. The patient had a history of Hodgkin
lymphoma at the age of 9 years, with complete clinical
and hematological remission after combined chemo- and
radiotherapy. It was recorded that the patient’s ailments, at
the time of presentation, had commenced at the age of 23
years, and 3 years later the osteolytic bone lesions in S1 and
L5 vertebrae were found on MRI and CT scans (Figures 1(a)
and 1(b)). No data of tuberculous osteitis was obtained. The
patient underwent a surgical resection of the S1 vertebral
body and spinal fusion with titanic block (Figure 1(c)). Six
months later, due to the progression in thoracic vertebrae,
the tunnel resection and radiothermoablation ofTh4 andTh7
were performed.
Postoperative material was prepared for histological
investigation and subsequent analysis revealed the foci of
fibrosis, within which there were groups of xanthoma cells
and multinuclear giant cells (Figures 2(a) and 2(b)); the
Reed-Sternberg cells were not detected. These cells stained
positively for CD68 (Figure 3(a)), but not CD1a. Less than
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Figure 1: Sagittal (a) and frontal (b) CT showing osteolytic bone lesions in S1, sized 2.9 ∗ 2.1 ∗ 2.2 cm. (c) Frontal X-rays of lumbosacral
region of spine, showing spinal fusion with titanic block.
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∗
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Figure 2: (a) Hematoxylin-eosin staining, ×100. (b) High-power view of hematoxylin-eosin staining, ×400. Arrows: groups of xanthoma
cells, arrowhead: giant multinuclear cell, stars: foci of fibrosis.
5% of the cells were S100 positive (Figure 3(b)), and 10–
15% were positive for factor XIIIa (Figure 3(c)). Such an
immunophenotype suggested that ECD was a plausible
explanation for the reported symptoms, and the relapse of
Hodgkin disease could be excluded as atypical cells with
CD30 and CD15 expression were not detected. At the PET-
scan, multiple foci of increased FDG uptake were identified
in C5, Th7–Th11, L3, L5 vertebrae, 3rd, 7th, and 8th left
ribs, the right pubic bone, and both iliac bones, with a
maximal size of 2.4 ∗ 3.9 cm in L3 and maximal SUV of
12.5 in Th7. Additional examination revealed autoimmune
thyroiditis with hypothyreosis. Therefore, we initiated the
therapy with L-thyroxine. In order to exclude the typical
organ involvement in ECD, we performed anMRI scan of the
central nervous system, which revealed no abnormalities. An
ultrasound of the abdomen, echocardiography, and thoracic
CT were also performed, which collectively demonstrated
no signs of aortic involvement, retroperitoneal fibrosis, or
any other pathological findings. Radiological investigation of
the long bones revealed neither osteolytic nor osteopetrotic
lesions; ophthalmological status was normal. There were no
signs of systemic inflammation and CRP and BSG levels
remained normal throughout the entire observation period.
TheBRAFV600Emutationwas detected in bonemarrow and
peripheral blood by MASA (mutant allele-specific amplifica-
tion) and is described in more than 50% of ECD cases [3, 4].
The detailed description of MASA technique is provided in
Supplement 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/876752.
Taking into account the foci of bone destruction with
signs of progression, bone pain, and verified diagnosis of
ECD, a therapy plan was commenced with alfa-interferon 3
million units 3 times per week, combined with zoledronic
acid 4mg once monthly. This therapy is now well tolerated
with only a moderate flu-like syndrome observed, which
is controlled by paracetamol and mild neutropenia, which
does not require therapy with colony-stimulating factors. At
follow-up, 2 years after the start of the therapy the patient
is pain-free and his overall quality of life has now much
increased. The PET-scan was repeated and revealed that
smaller foci (maximal size – 1.5 ∗ 2.3 cm in L3) of increased
FDG uptake persisted only in Th7–Th9, L1, and L3, with
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Figure 3: Immunohistochemistry. (a) Staining for CD68, ×200. Prominent expression of CD68 in xanthoma and giant multinuclear cells.
(b) Staining for S-100, ×400. Less than 5% of the xanthoma cells express S-100. (c) Staining for FXIIIa, ×400. 10–15% xanthoma cells have
nuclear-cytoplasmic expression of FXIIIa.
maximum SUV of 1.6. This affirmed a marked improvement
in the course of this patient’s disease.
3. Discussion
This case report presents ECD diagnosed at an early
stage with unusual spine and pelvic involvement, without
extraskeletal manifestations. It is of interest that the patient
had a lymphoproliferative disease in his childhood, but the
potential relationship between these two diseases remains
to be elucidated. To date, there is only one published case
report where ECD occurs after acute lymphoblastic leukemia
in childhood [5]. An early diagnosis is important in order to
start disease-modulating therapy, which may improve prog-
nosis and survival of patients, and is of significant importance
to active clinical studies recruiting for this disorder. At the
time of diagnosis, specific therapy utilizing a BRAF inhibitor
(vemurafenib), which may be the best therapeutic option
in the presence of the BRAF mutation, was not available
in the Russian Federation. Moreover, experience with BRAF
inhibition is lacking in the treatment of ECD worldwide,
although the current results of this treatment option in a
small patient cohort appear promising with an objective of
sustained clinical improvement and good tolerability [6].
Other therapeutic options for this patient could be to prevent
the biologic activity of the proinflammatory cytokines, with
a recombinant, nonglycosylated form of the human IL-1
receptor antagonist (anakinra), or infliximab, an antagonist
of TNF-alpha; however, taking into account the expected life-
long treatment and corresponding financial expenses, this
treatment was considered to be unacceptable. Furthermore,
the expected side effects of these drugs together with the
lack of systemic inflammation throughout the monitored
course of the disease strengthened our decision against this
treatment. It is known that alfa-interferon enhances the
terminal differentiation of histiocytes and dendritic cells
[7] and many clinical cases have shown its efficacy [8–11].
Therefore, the administration of this drug in our patient with
ECD seemed to be a logical, promising treatment. Due to
the lack of other systemic involvements, we also combined
interferon with the aminobisphosphonate (zoledronic acid),
based on good clinical outcomes in previously described
patients receiving this therapy [12–14]. This clinical case
shows a very good response and tolerability of this treatment
combination, implying further investigation of its safety and
duration of response.
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